Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SPR | P35270 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13519180 | 0.92 | SPR (0.61) | EPHX2ALDH1A1HTTSPRCHRNB2 | |
| SCHEMBL19741109 | 0.92 | SPR (0.61) | EPHX2ALDH1A1HTTSPRCHRNB2 | |
| SCHEMBL27145844 | 0.85 | SPR (0.51) | EPHX2ALDH1A1HTTSPRCHRNB2 | |
| SCHEMBL5271411 | 0.83 | EPHX2 (0.59) | EPHX2 | |
| SCHEMBL6123504 | 0.82 | SPR (0.60) | EPHX2ALDH1A1HTTSPRHRH3 | |
| SCHEMBL639198 | 0.82 | EPHX2 (0.60) | EPHX2ALDH1A1HTT | |
| SCHEMBL639943 | 0.82 | GPR119 (0.63) | EPHX2ALDH1A1HTTSPR | |
| SCHEMBL7368825 | 0.81 | EPHX2 (0.59) | EPHX2ALDH1A1HTTSPR | |
| SCHEMBL2453004 | 0.81 | GPR119 (0.52) | EPHX2ALDH1A1HTTSPR | |
| SCHEMBL30775373 | 0.80 | SPR (0.58) | EPHX2ALDH1A1HTTSPRCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066659-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| EP-2356101-B1 | PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2393803-A1 | SUBSTITUTED INDOLE COMPOUNDS AS BRADYKININ RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-2356101-A1 | PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2350003-A1 | SUBSTITUTED DISULFONAMIDES AS BRI-MODULATORS | Grünenthal GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010089084-A1 | SUBSTITUTED INDOLE COMPOUNDS AS BRADYKININ RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010051977-A1 | SUBSTITUTED DISULFONAMIDES AS BRI-MODULATORS | Grünenthal GmbH (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010046109-A1 | PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | disclosed |
| EP-2066659-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008040492-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-04-10 | — | — | WO | disclosed |
| EP-1347990-B1 | Peptides having inhibiting activity to nitric oxyde production | ASTELLAS PHARMA INC (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7129243-B2 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20040097425-A1 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1347990-A2 | PEPTIDE MIT INHIBIERENDER AKTIVITÄT ZUR PRODUKTION VON STICKSTOFFMONOXID | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002055541-A2 | PEPTIDES HAVING INHIBITING ACTIVITY ON THE PRODUCTION OF NITRIC OXIDE | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097425-A1 | Peptide compounds | VIP, NOS1, NOS3 | EPHX2 3846/4885ALDH1A1 1225/4885HTT 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.